Apollo Endosurgery, Inc. to Report Second Quarter Results on July 23, 2019

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

AUSTIN, Texas–(BUSINESS WIRE)–Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended June 30, 2019 on Tuesday, July 23, 2019, after the U.S. stock markets close.

Apollo will hold a conference call on Tuesday, July 23, 2019 at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers. The conference ID number is 3369396. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.apolloendo.com.

A replay of the webcast will be made available on Apollo’s website, www.apolloendo.com, shortly after completion of the call.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol “APEN”. For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contacts

Apollo Endosurgery, Inc.

John Gillings, 512-279-5100

Investor Relations

investor-relations@apolloendo.com

Staff

Recent Posts

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)…

2 hours ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology…

2 hours ago

Entourage Health Corp. Announces Closing of Plan of Arrangement

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:…

2 hours ago

Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical…

2 hours ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase…

2 hours ago

AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants

 Al Zeyoudi: "Hosting such major international events reflects the UAE's pivotal role as a global…

5 hours ago